Cellectis reports positive financial results, progress in clinical programs, and partnerships with key industry players.

From GlobeNewswire: 2024-11-04 16:30:00

Cellectis provided updates on their clinical programs, including UCART22 and UCART20x22, with enrollment ongoing and a Phase 1 dataset and late-stage development strategy set to be presented in 2025. They also highlighted R&D activities in partnership with AstraZeneca for three programs. Adrian Kilcoyne, an industry leader, was appointed as Chief Medical Officer. The company reported a cash position of $264 million as of September 30, 2024, with a cash runway projection into 2027.

Cellectis continues to focus on enrolling patients in the BALLI-01 and NATHALI-01 studies, evaluating UCART22 and UCART20x22, respectively. They have deprioritized the development of UCART123. Additionally, Cellectis published a scientific article suggesting MUC1 CAR T-cells could be a potential treatment for triple-negative breast cancer. Partnerships with Servier, Allogene, and AstraZeneca are progressing, with ongoing trials and data updates expected.

The appointment of Adrian Kilcoyne as Chief Medical Officer brings valuable experience to Cellectis as they progress in clinical programs and partnerships. Financially, the company reported a cash position of $264 million as of September 30, 2024, with a cash runway projection into 2027. Cellectis also reported positive revenue growth and a reduction in net loss compared to the previous year. Adjusted net income for shareholders improved in the third quarter and nine-month period of 2024.

Cellectis is a clinical-stage biotechnology company focused on using gene-editing platforms to develop cell and gene therapies. They are advancing CAR T immunotherapies and gene editing in hemopoietic stem cells for various diseases. With key partnerships and ongoing clinical trials, Cellectis is committed to bringing potentially life-saving therapies to patients with unmet medical needs.



Read more at GlobeNewswire:: Cellectis Provides Business Updates and Financial Results